pharmacokinetics PK

Related by string. pharmacokinetic PK * Pharmacokinetics . Pharmacokinetic : safety tolerability pharmacokinetics . safety tolerability pharmacokinetic . favorable pharmacokinetic profile . tolerability pharmacokinetics / PKS . PKs . Pk : Lt Gen PK Rath . PK Banerjee . PK Narayana Panicker * pharmacokinetic PK study . pharmacokinetic PK profile . formal pharmacokinetic PK *

Related by context. All words. (Click for frequent words.) 79 safety tolerability pharmacokinetic 79 pharmacodynamics PD 77 pharmacodynamic PD 75 safety tolerability pharmacokinetics 74 pharmacokinetic parameters 74 pharmacokinetics 73 pharmacokinetic PK 73 pharmacodynamic effects 73 analgesic efficacy 72 pharmacokinetic pharmacodynamic 72 pharmacodynamics 72 pharmacodynamic 72 tolerability 71 viral kinetic 71 preclinical efficacy 71 tolerability pharmacokinetics 71 ascending doses 71 Pharmacokinetics PK 71 pharmacokinetics pharmacodynamics 71 Phase Ib clinical 70 Pharmacokinetic 70 pharmacokinetic PK profile 70 pharmacokinetic profile 70 pharmacodynamic profile 70 ascending dose 70 galiximab 70 multicentre randomized 70 pharmacokinetic PK study 70 dose escalation trial 69 tolerated dose MTD 69 pharmacokinetic 69 blinded randomized placebo controlled 69 pharmacodynamic properties 69 Phase 1a 69 ORMD 69 safety tolerability 69 pharmacokinetic profiles 69 pharmacodynamic markers 68 Phase IIa clinical 68 Phase 1b trial 68 phase Ib 68 Pharmacokinetic PK 68 antiviral efficacy 68 ritonavir boosted 68 Phase Ia 68 subcutaneously administered 68 teriflunomide 68 Phase 1b clinical 68 fosbretabulin 68 multicenter Phase II 68 multicenter randomized placebo controlled 68 Phase 2a clinical 68 solithromycin 68 single ascending dose 68 viral kinetics 68 Phase 1a clinical 67 limiting toxicity DLT 67 pharmacokinetic characteristics 67 randomized multicenter 67 efficacy tolerability 67 vidofludimus 67 Phase Ib study 67 GAMMAGARD 67 Primary endpoints 67 dose escalation study 67 Phase 1b 67 DLTs 67 Initiated Phase 67 Pharmacodynamic 67 dose proportionality 67 noninferiority 67 multiple ascending dose 67 thorough QT 67 crizotinib PF # 67 Phase IIa trial 67 Phase Ib 67 Phase Ib II 67 dose escalation Phase 67 relapsed MM 67 SCH # 67 efficacy 66 melphalan prednisone 66 CDK inhibitor 66 phase 2a 66 favorable pharmacokinetic profile 66 placebo controlled clinical 66 randomized multicenter trial 66 Secondary endpoints 66 dose escalation clinical 66 prospectively defined 66 multicenter randomized controlled 66 varespladib 66 desvenlafaxine succinate 66 randomized Phase III 66 Omacetaxine mepesuccinate 66 secondary efficacy endpoints 66 TMC# C# 66 masked placebo controlled 66 double blinded placebo 66 #mg QD [002] 66 genotypic resistance 66 pharmacokinetic studies 66 multicenter Phase III 66 velafermin 66 neratinib 66 PRTX 66 rNAPc2 66 prucalopride 66 phase IIa clinical 66 Teriflunomide 66 subcutaneous SC 66 oral prodrug 66 placebo controlled dose escalation 66 dose cohort 66 Randomized controlled 66 multicenter randomized 65 davunetide intranasal AL 65 nab paclitaxel 65 phase IIb 65 MAGE A3 ASCI 65 active comparator 65 urate lowering 65 Phase 2b clinical 65 alvespimycin 65 prospective randomized controlled 65 immunogenicity 65 huN# DM1 65 abacavir lamivudine 65 S/GSK# 65 tolerability profiles 65 nucleotide analog 65 RE SURGE 65 Phase 2b study 65 GOUT 65 Maximum Tolerated Dose MTD 65 phase IIb clinical 65 phase IIa 65 dose cohorts 65 CANCIDAS 65 treatment naive genotype 65 PEG IFN 65 maximally tolerated dose 65 Tarceva TM 65 Phase IIIb clinical 65 Pharmacokinetic studies 65 phase IIIb 65 dosing regimens 65 investigational protease inhibitor 65 Enzastaurin 65 randomized crossover 65 plasma pharmacokinetics 65 preclinically 65 pomalidomide 65 pertuzumab 65 CIMZIA TM certolizumab pegol 65 RE LY ® 65 oral rivaroxaban 65 dose limiting toxicities 65 reactogenicity 65 Kahalalide F 65 elotuzumab 65 PSN# [002] 65 DermaVir Patch 65 Capesaris 65 nonrandomized 64 dosage regimens 64 Secondary endpoints include 64 double blinded randomized 64 RE LY 64 liposomal amphotericin B 64 intermittent dosing 64 antiviral activity 64 NP2 Enkephalin 64 ALB # 64 pharmacodynamic parameters 64 Phase IIIb 64 dose dose escalation 64 phase IIb study 64 QD dosing 64 Phase 2a trial 64 administered subcutaneously 64 selective modulator 64 Phase IIa 64 virus HCV protease inhibitor 64 anti leukemic 64 tipifarnib 64 mg kg dose 64 atazanavir ritonavir 64 prospective multicenter 64 ongoing Phase 1b 64 ascending dose study 64 CLORETAZINE TM VNP#M 64 NOX E# 64 Afatinib 64 Darusentan 64 VELCADE melphalan 64 BAL# [002] 64 selective agonist 64 Traficet EN 64 placebo controlled 64 riociguat 64 RG# ITMN 64 randomized Phase 2b 64 Cloretazine 64 fluticasone furoate 64 Phase 2b clinical trials 64 zonisamide SR 64 EGFR HER2 64 JAK inhibitor 64 pharmacodynamic endpoints 64 #mg BID [003] 64 oral deforolimus 64 Tolerability 64 virologic 64 posaconazole 63 biodistribution 63 STRIDE PD 63 APTIVUS 63 MEND CABG 63 chlorambucil 63 safety tolerability pharmacodynamics 63 subanalysis 63 Phase #b/#a 63 NSABP B 63 AKT inhibitor 63 Phase #/#a 63 liver histology 63 LEXIVA r 63 ganetespib 63 demonstrated antitumor activity 63 receptor inhibitor 63 tipranavir r 63 Phase Ib clinical trials 63 Immunogenicity 63 assessing T DM1 63 label multicenter 63 TRANSFORMS 63 BRIM3 63 lomitapide 63 Phase IIb III 63 pain palliation 63 Ophena TM 63 Multimeric 63 epoetin alpha 63 BRIM2 63 mg kg BID 63 antitumor activity 63 mg TID 63 trastuzumab emtansine T DM1 63 novel VDA molecule 63 label dose escalation 63 evaluating tivozanib 63 NOXAFIL Oral Suspension 63 Secondary endpoints included 63 tolerability profile 63 polymerase inhibitor 63 PKC# 63 placebo controlled Phase 63 vicriviroc 63 TAXUS V 63 preclinical pharmacokinetic 63 liposomal formulation 63 ENMD # 63 IMGN# 63 multicenter Phase 63 pharmacokinetic properties 63 coadministration 63 antithrombotic 63 bendamustine 63 Azedra 63 AEGR 63 RSD# oral 63 mg QD 63 favorable tolerability 63 randomized blinded 63 inhibitor RG# 63 CIMZIA ™ 63 confirmatory clinical 63 orally bioavailable 63 dose regimens 63 MAP# 63 QTc prolongation 63 Engerix B 63 controlled multicenter Phase 63 Phase IIb clinical 63 #mg/day [001] 63 AST ALT 63 Tyrima 63 ZACTIMA 63 achieved statistical significance 63 hematological parameters 63 TAXUS VI 63 cariprazine 63 RE LY trial 62 optimal dosing 62 antibody titer 62 darunavir ritonavir 62 HGS ETR2 62 pharmacodynamic profiles 62 IFN α 62 EDEMA3 62 placebo controlled randomized 62 ruxolitinib 62 VEGF inhibitor 62 PPAR gamma agonist 62 ExTRACT TIMI 62 aclidinium bromide 62 multivariate Cox 62 sorafenib Nexavar 62 intravenous dosing 62 mapatumumab 62 tanespimycin 62 INCB# [001] 62 satraplatin Phase 62 endothelin antagonists 62 budesonide MMX 62 R#/MEM # 62 Imprime PGG 62 ZYBRESTAT fosbretabulin 62 pharmacokinetic equivalence 62 CCR5 antagonist 62 Phase III multicenter 62 randomized discontinuation trial 62 Phase #b/#a trial 62 paricalcitol 62 Vidaza azacitidine 62 erlotinib Tarceva ® 62 SPIRIT FIRST 62 EURIDIS 62 prospective randomized multicenter 62 cannabinor 62 Deforolimus 62 cathepsin K inhibitor 62 relapsed MCL 62 QT QTc 62 pegylated liposomal doxorubicin 62 HCV SPRINT 62 urinary N telopeptide 62 Antiviral Activity 62 cilengitide 62 PS# [001] 62 APPRAISE 62 serum cortisol 62 MEND CABG II 62 erythropoietic 62 mertansine 62 axitinib 62 CHAMPION PCI 62 DASISION 62 CBLC# 62 CIMZIA TM 62 Denufosol 62 Aclidinium 62 Dual Opioid 62 protease inhibitor PI 62 doxorubicin docetaxel 62 sulodexide 62 serum concentrations 62 hemostatic efficacy 62 dacetuzumab 62 cynomolgus monkeys 62 alicaforsen enema 62 PEGylated interferon beta 1a 62 receptor tyrosine kinase inhibitor 62 CYT# 62 Logistic regression 62 composite endpoint 62 efficacy endpoints 62 ON #.Na 62 systemically administered 62 LUX Lung 62 clevidipine 62 azilsartan medoxomil 62 HCV replicon 62 ToGA 62 certolizumab 62 neurologic progression 62 Pharmacokinetic parameters 62 Secondary efficacy endpoints 62 ancrod 62 APTIVUS r 62 beta 1a 62 efficacy endpoint 62 indibulin 62 urocortin 2 62 investigational oral 62 ACTEMRA TM 62 Androxal TM 62 GLYX 62 PI3K/Akt pathway inhibitor 62 orally administered inhibitor 62 orally inhaled migraine 62 label multicenter Phase 62 Pemetrexed 62 randomized Phase IIb 62 prospective multicentre 62 Sym# 62 tecarfarin 62 REMINYL ® 62 prospective multicenter randomized 62 mcg dose 62 novel histone deacetylase 62 NTx 62 TASKi2 62 PXD# 62 Phase III placebo controlled 62 enzastaurin 62 VKORC1 62 genotoxicity 61 platelet inhibitor 61 FOLPI 61 NGX# 61 pan HDAC inhibitor 61 metastatic HRPC 61 Aflibercept 61 Archexin 61 Kaplan Meier analysis 61 demonstrated clinically meaningful 61 PSMA ADC 61 olmesartan 61 PRE SURGE 61 double blind placebo 61 dexpramipexole 61 HCD# [002] 61 LibiGel Phase III 61 randomized multicenter Phase III 61 TMC# [002] 61 rHuPH# 61 XL# SAR# 61 HMG CoA reductase inhibitors 61 mg/m2 dose 61 PREVENT IV 61 LAB CGRP 61 dosed orally 61 tigecycline 61 CRLX# 61 HGS# 61 TMC# r 61 Blinatumomab 61 blind randomized placebo 61 Ceplene/IL-2 61 budesonide foam 61 decitabine 61 gemcitabine Gemzar ® 61 treatment naïve genotype 61 antitumor effect 61 randomized controlled Phase 61 pramlintide metreleptin combination 61 plus prednisone 61 oral ridaforolimus 61 PRIMO CABG 61 Phase 2b trial 61 gemcitabine carboplatin 61 controlled multicenter 61 LCP AtorFen 61 pharmacokinetic pharmacodynamic PK PD 61 ELACYT 61 antidepressant efficacy 61 mecamylamine 61 investigational humanized monoclonal antibody 61 ROCKET AF 61 trodusquemine 61 Zoraxel 61 relapsing multiple sclerosis 61 Cloretazine R VNP#M 61 EOquin TM 61 multidose 61 K ras mutations 61 dyskinesia PD LID 61 CYP#D# inhibitor 61 multicenter randomized double 61 adalimumab 61 HuMax EGFr 61 plasma renin activity 61 serum antibody 61 randomized multicentre 61 PRECiSE 61 mg BID 61 CLL SLL 61 topically administered 61 INCB# [003] 61 weekly subcutaneous injections 61 MetMAb 61 refractory prostate cancer 61 registrational trial 61 tumorigenicity 61 Xanafide 61 randomized placebo controlled 61 recurrent glioblastoma multiforme 61 #mg dose [001] 61 OMP #M# 61 Doxil ® 61 Phase 2b monotherapy 61 hemagglutination inhibition HAI 61 prospectively randomized 61 Phase III randomized controlled 61 peginterferon alpha 2a 61 INC# 61 refractory CLL 61 Initiate Phase 61 primary hypercholesterolemia 61 bicifadine 61 retaspimycin 61 placebo controlled studies 61 cobiprostone 61 sunitinib Sutent ® 61 NO# [002] 61 visilizumab 61 blinded randomized 61 irbesartan 61 Panzem R NCD 61 CYP#C# genotype 61 Prostate AdenoCarcinoma Treatment 61 LCP Tacro 61 GSK# [001] 61 Double Blind Randomized 61 beta2 agonist 61 AVADO 61 forodesine 61 histone deacetylase inhibitor 61 lanthanum carbonate 61 dosing cohort 61 RoACTEMRA 61 phase Ib clinical 61 Omacetaxine 61 prospective randomized placebo 61 hemagglutination inhibition 61 Kinoid 61 blinded placebo controlled 61 afatinib 61 adecatumumab 61 fluvastatin 61 blind randomized controlled 61 ADAGIO study 61 rFSH 61 subcutaneous formulation 61 Phase 1b clinical trials 61 effector function 61 docetaxel chemotherapy 61 HCV RESPOND 2 61 prostate cancer CaP 61 non nucleoside 61 glatiramer acetate 61 Spiegelmer ® 61 Subgroup analysis 61 KRAS mutations occur 61 INCB# [002] 61 REVIVE Diabetes 61 TPI ASM8 61 dosing cohorts 61 antibody titers 61 Safinamide 61 CCX# 61 MIRCERA 61 apremilast 61 Phase III confirmatory 61 MGd 61 non inferiority 61 alfa 2a 61 lispro 61 estramustine 61 mGluR5 NAM 61 tasimelteon 61 serotonin norepinephrine reuptake inhibitor 61 lenalidomide Revlimid 61 GetGoal Phase III 61 interleukin IL -# 61 CTA# Injection 61 Cmax 61 tumor histology 61 PDE4 inhibitor 61 dose dependently 61 TAXUS ATLAS 61 Randomised 61 Oral NKTR 61 TBC# 61 adenoma recurrence 61 Phase 2b 61 somatostatin analog 61 univariate 61 multicenter prospective 60 daily subcutaneous injections 60 Phase IIb 60 baminercept 60 definite stent thrombosis 60 EmbraceAC 60 subcutaneous dose 60 Amrubicin 60 nonclinical studies 60 xenograft models 60 AIR CF1 60 sorafenib Nexavar ® 60 insulin detemir 60 Phase IIb clinical trials 60 μg kg 60 ORENCIA ® 60 CALGB # [002] 60 Phase 2a 60 prostate cancer PCa 60 immunomodulator 60 Phase III randomized 60 postmenopausal osteoporotic women 60 prospective observational 60 unfractionated heparin UFH 60 progression TTP 60 cardioprotective effects 60 caspofungin 60 ATACAND 60 ADVANCE PD 60 mg qd 60 MEK inhibitor 60 daunorubicin 60 CTAP# Capsules 60 ZD# [001] 60 R# #mg BID 60 timepoints 60 elacytarabine 60 ChronVac C R 60 aspartate aminotransferase 60 AEG# 60 Adalimumab 60 Multiple Ascending Dose 60 PDX pralatrexate 60 Prodarsan ® 60 PRT# 60 telaprevir dosed 60 thalidomide Thalomid 60 motesanib diphosphate 60 Pharmacokinetic Study 60 Onconase 60 generation FBPase inhibitor 60 dose dexamethasone 60 receptor blocker 60 TACI Ig 60 dose escalation phase 60 Apoptone 60 Pivotal Phase III 60 Pralatrexate 60 Virulizin ® 60 PegIFN 60 bortezomib Velcade R 60 Phase IIA 60 mg/m2 cohort 60 hA# 60 dasatinib 60 radezolid 60 balsalazide tablet 60 blind randomized 60 RRMS patients 60 QTc 60 Carotid Revascularization Endarterectomy vs. 60 DU #b 60 boosted protease inhibitor 60 subcutaneous PRO 60 ABC/3TC 60 efavirenz EFV 60 serum phosphorous 60 virological response 60 lisdexamfetamine dimesylate 60 MGN# 60 mg RDEA# 60 mCRC patients 60 mcg doses 60 CEQ# 60 ara C 60 Zemplar Capsules 60 IFN beta 60 FOLFOX6 chemotherapy regimen 60 PEG SN# 60 DEB# 60 investigational hepatitis C 60 MVA MUC1 IL2 60 virologic response 60 BMS # 60 preclinical pharmacology 60 EXPAREL ™ 60 XL# inhibits 60 Phase 1b dose escalation 60 5alpha reductase 60 GRN#L 60 mRCC 60 XL# XL# XL# 60 GRNCM1 60 imetelstat 60 L PPDS 60 PF # [001] 60 evaluating Vectibix 60 glufosfamide 60 clomipramine 60 Cloretazine R 60 intranasal formulation 60 comparator arm 60 hsCRP levels 60 sipuleucel T 60 ispinesib administered 60 Degarelix 60 torezolid 60 Inhalation Solution 60 ISIS # 60 morphometric vertebral fractures 60 intravesical 60 selective antagonist 60 PA# [002] 60 Carfilzomib 60 neoadjuvant 60 oblimersen 60 placebo controlled clinical trials 60 pitavastatin 60 AAG geldanamycin analog 60 hepatic fibrosis 60 azacitidine 60 HER2 expression 60 ug kg 60 plus dexamethasone 60 zotarolimus 60 QLT# 60 6R BH4 60 EGS# 60 TNFalpha 60 Triapine R 60 adecatumumab MT# 60 depsipeptide 60 non nucleoside inhibitor 60 CALGB 60 thymalfasin 60 CA9 SCAN 60 Aplidin 60 Zoraxel TM 60 PEG PAL 60 sunitinib malate 60 GW# [003] 60 CK # administered 60 abiraterone acetate 60 CA4P 60 peginterferon alfa 2a #KD 60 corrected QT interval 60 JVRS 60 noninferior 60 PENNVAX B 60 pharmacodynamic PK PD 60 celgosivir 60 cetuximab Erbitux R 60 delafloxacin 60 multivariate logistic regression 60 IMA# 60 Luteinizing Hormone Releasing Hormone 60 tirofiban 60 low dose cytarabine 60 Randomized Double blind 60 ataluren 60 Trandolapril 60 nucleoside analog 60 CIMZIA R 60 MERLIN TIMI 60 PERSEUS 60 metaglidasen 60 CR CRu 60 BARACLUDE ® 60 rFIXFc 60 lead Aganocide compound 60 multicenter phase 60 Hsp# Inhibitor 60 RELOVAIR ™ 60 GSK# [002] 60 insulin lispro 60 PK PD 60 stated Michelle Berrey 60 Preclinical studies 60 placebo controlled Phase III 60 long acting muscarinic 60 p# biomarker 60 doxorubicin cyclophosphamide 60 humanized anti 60 randomized controlled multicenter 60 ritonavir boosted atazanavir 60 huC# DM4 60 ATL# [001] 60 dose pharmacokinetic 60 RezularTM 60 multicentre 60 XOMA 3AB 60 PREZISTA r 60 Vacc 4x 60 SAR# [002] 60 ribavirin RBV 60 relapsed refractory multiple myeloma 60 ADAS Cog 60 rapid virologic response 60 Quinamed 60 IMC A# 60 GH deficiency 60 peginterferon alfa 2b 60 vivo toxicology 60 Echocardiographic 60 receptor antagonists 60 peripheral blood mononuclear 60 #:# randomization 60 edoxaban 60 dasatinib Sprycel ® 60 lactate dehydrogenase LDH 60 EMPHASIS HF trial 60 apolipoproteins 60 TO AVOID PREGNANCY WHILE 60 confirmatory Phase III 60 Phase 2b randomized 60 NS5B polymerase 60 HER2 positive metastatic breast 60 direct thrombin inhibitors 60 label multicenter randomized 60 BAY #-# 60 vitro cytotoxicity 60 Val HeFT 60 DB# [003] 60 logistic regression models 60 Phase IIa trials 60 ABSORB trial 60 PRIMO CABG2 60 Phenoptin 60 basal bolus regimen 60 Aurexis 60 CG# [003] 60 BEXXAR Therapeutic Regimen 60 XIENCE V PROMUS Stent 60 inecalcitol 60 dasatinib Sprycel 60 GRNVAC1 60 ASTEROID 60 temsirolimus 60 evaluating Actimmune 60 FOLOTYN ® 59 Plasma concentrations 59 monotherapy 59 Sapacitabine 59 blind placebo 59 Randomized Phase 59 multicenter placebo controlled 59 blind placebo controlled 59 aflibercept VEGF Trap 59 longitudinal cohort study 59 bortezomib Velcade 59 Aptivus ® 59 Oral Fingolimod 59 Pharmacodynamics 59 regorafenib 59 HQK 59 retrospective cohort 59 patients evaluable 59 CAMMS# 59 Iloperidone 59 Phase IIIb study 59 μg dose 59 bioequivalency 59 Medidur TM FA 59 IIa trials 59 HGS ETR1 59 2 methoxyestradiol 59 divalproex sodium 59 randomized clinical 59 BIM #A# 59 farletuzumab 59 papillary renal cell carcinoma 59 glycosylated hemoglobin levels 59 prognostic significance 59 TASKi3 59 subgroup analyzes 59 hypoxia activated prodrug 59 ONTARGET 59 microsomal 59 Adenoma Prevention 59 Sibutramine Cardiovascular Outcomes 59 Bezielle 59 Folfox 59 Multivariate logistic regression 59 teduglutide 59 #beta estradiol 59 PEGPH# 59 DAPT 59 sitaxsentan 59 ZOLINZA 59 Vascugel ® 59 liver transplant recipients 59 EZN 59 interferon gamma 1b 59 pharmacokinetic interactions 59 unblinded 59 chronic myeloid 59 SPRYCEL ® 59 selective kinase inhibitor 59 MORAb 59 ULORIC 59 GLP toxicology studies 59 Ozarelix 59 antibody MAb 59 proteasome inhibitor 59 TOLAMBA 59 genotypic 59 hENT1 59 metabolic parameters 59 AZD# 59 EOquin 59 GRAVITAS trial 59 imatinib resistant 59 Pharmacokinetics 59 NATRECOR ® 59 HBsAg 59 gefitinib Iressa 59 Insulin PH# 59 iloprost 59 mg dose 59 aclidinium 59 orally dosed 59 CLARITY study 59 antiretroviral naïve 59 oral antiviral 59 immunostaining 59 evaluable patients 59 adalimumab Humira 59 PARTNER Trial 59 Prospective Randomized 59 5 Fluorouracil 59 immunological responses 59 Epirubicin 59 midstage clinical 59 HCV polymerase inhibitor 59 DCCR 59 neuroprotective effects 59 Seliciclib 59 Q#IR 59 metastatic castration resistant 59 randomized controlled clinical 59 randomized controlled 59 KRAS status 59 favorable pharmacokinetic 59 hyaluronidase enzyme 59 PI3K/mTOR 59 plasma concentrations 59 trabedersen 59 FFNS 59 generation NNRTI 59 anti HBs 59 CR# vcMMAE 59 serum leptin 59 tiotropium 59 elvitegravir 59 INSPIRE Trial Phase III 59 CorVue ™ 59 serum phosphorus 59 bosentan 59 metastatic renal cell carcinoma 59 STELARA 59 Tanespimycin 59 Phase III clinical 59 inhaled iloprost 59 TLK# 59 refractory NSCLC 59 VP# [004] 59 Tolvaptan 59 pan histone deacetylase 59 nelfinavir 59 mTOR inhibitors 59 RG# [001] 59 evaluable 59 abacavir Ziagen 59 mcg kg 59 Cytochrome P# 59 Triolex 59 prospective cohort 59 bevacizumab Avastin ® 59 undetectable HBV DNA 59 busulfan 59 plus COPEGUS 59 Lp PLA 2 59 antiangiogenic therapy 59 DAS# CRP 59 IPL# 59 Linagliptin 59 IMPACT DCM 59 Phase IIB 59 registrational Phase 59 uricase 59 Posiphen 59 difluprednate 59 maximal dose 59 LEVADEX 59 lintuzumab 59 liposomal doxorubicin 59 relapsed myeloma 59 Multiple Myeloma MM 59 colorectal adenoma 59 USL# 59 hour bronchodilation 59 piperacillin tazobactam 59 Aplidin R 59 prespecified 59 KRN# 59 Pegasys plus Copegus 59 HBeAg negative patients 59 DAVANAT 59 cMET

Back to home page